Pacific Edge edges closer to its Medicare moment

Pacific Edge has delivered a modest but important improvement in fourth quarter test volumes, with total laboratory throughput rising 2.7% from the previous quarter to 5,582 tests. That is hardly champagne-cork territory, but it does matter because the gain came while the company was juggling a transition away from Cxbladder Detect, selling into a US market where Medicare still does not reimburse key products, and running with a leaner sales team after cost-saving measures.

The mix of growth was also telling. US volumes rose 1.0% to 4,064 tests, with Kaiser Permanente Southern California doing much of the heavy lifting, while Asia Pacific volumes climbed 7.7% to 1,518. Even so, the broader picture remains one of a business still rebuilding from the setback of Medicare non-coverage. Volumes are improving sequentially, but they remain well below the levels Pacific Edge was reporting a year earlier. For investors, that underlines a central point - the immediate story is less about booming sales and more about whether reimbursement and policy settings are finally turning in the company’s favour.

Medicare could be the circuit breaker

That is where the latest progress with Novitas becomes crucial. Pacific Edge says the February Contractor Advisory Committee hearing delivered strong support from expert clinicians for urine-based biomarkers in hematuria assessment, including the role of Cxbladder Triage and Triage Plus. The company believes Novitas now has the information needed to produce a draft local coverage determination by the end of September 2026, with final effective coverage potentially following about six months later.

Investors should not confuse that with money in the bank just yet. Draft policy is not final policy, and final policy is not the same as instant revenue acceleration. Still, this is the clearest sign yet that the Medicare door may be reopening. Chief executive Dr Peter Meintjes described the company as being "on the cusp of a major commercial inflection point", which is management shorthand for saying the next big swing factor is no longer test performance, but payment.

If Pacific Edge can secure positive Medicare coverage, the effect could stretch well beyond the federal payer system. Medicare recognition often acts as a quality stamp for the broader market, particularly in diagnostics, where clinicians, hospitals and private insurers tend to take their cues from formal coverage decisions.

Commercial payers are starting to move

That read-through is already emerging in the private market. Cxbladder Triage has now won coverage from Blue Cross Blue Shield of North Carolina and South Carolina, representing about 4.2 million covered lives combined, while Highmark has adopted policy for Cxbladder Monitor across its 7 million covered lives. Together, those wins take Pacific Edge’s newly addressed commercial population to 11.2 million people.

The significance is not just the numbers. These policies mirror language published by Avalon Healthcare Systems, suggesting third-party policy support can influence insurer adoption. That matters because Pacific Edge is effectively building a commercial reimbursement template one payer at a time. The company has also been explicit that policy adoption is the first step, with contracting and pricing still needed before the full revenue benefit shows through. In plain English, policy wins are encouraging, but investors should watch average selling prices and reimbursement receipts before declaring victory.

Encouragingly, the company says these commercial payers cover more than twice the patient population reached through Kaiser Permanente Southern California. That suggests the addressable market is widening, even if the revenue conversion will take time.

APAC progress adds another string to the bow

Pacific Edge also notched meaningful wins closer to home. Singapore General Hospital will incorporate Triage, Triage Plus and Monitor into patient care, while Townsville University Hospital has begun clinical use of Triage Plus and Monitor. These are strategically useful additions because they show the products gaining traction in real clinical pathways, not just in trial settings or sales decks.

The Townsville adoption is particularly interesting operationally, with nurses leading test ordering under a consultant-backed protocol. That hints at workflow advantages that could support broader adoption, especially in regional settings where specialist access is more limited.

Meanwhile, Pacific Edge has filed a Patent Cooperation Treaty application for Triage Plus, covering its multi-modal approach combining DNA single nucleotide variants with existing mRNA biomarkers and algorithmic analysis. That does not create immediate earnings, but it helps reinforce the moat around the next generation of the platform.

What investors should watch now

The next chapter is fairly clear. Investors should track three things: whether Novitas publishes a positive draft Medicare policy by September, whether commercial payer wins translate into better pricing and reimbursement, and whether clinical evidence continues to strengthen adoption. On that last point, the AUSSIE study’s preliminary data won Best Oncology Presentation at the USANZ conference, giving Pacific Edge another credibility tick with clinicians.

For now, Pacific Edge remains a policy-driven diagnostics story rather than a straight volume-growth tale. The fourth quarter numbers suggest the business is steadying. The real test is whether reimbursement momentum finally turns scientific promise into commercial traction.